U.K. may be near 60M dose deal with Sanofi, GSK for second COVID-19 vaccine partnership

The U.K. is reportedly in talks to secure access to a second COVID-19 vaccine, this time from GlaxoSmithKline and Sanofi, as concerns grow over vaccine nationalism.

The government has already partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) for 100 million doses of AZD1222, the COVID-19 vaccine it's developing with the University of Oxford. AZD1222 is in a Phase II/III trial in the U.K. (see “U.K. Expects First Access on Oxford Vaccine”)...